Header Logo

Connection

THOMAS WHEELER to Prostate-Specific Antigen

Back to Details
This is a "connection" page, showing publications THOMAS WHEELER has written about Prostate-Specific Antigen.
THOMAS WHEELER
Connection Strength
1.253
Prostate-Specific Antigen
  1. Metabolomic signatures of aggressive prostate cancer. Prostate. 2013 Oct; 73(14):1547-60.
    View in: PubMed
    Score: 0.095
  2. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn. 2013 Mar; 15(2):270-9.
    View in: PubMed
    Score: 0.091
  3. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.
    View in: PubMed
    Score: 0.064
  4. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol. 2004 Sep; 172(3):900-4.
    View in: PubMed
    Score: 0.051
  5. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
    View in: PubMed
    Score: 0.050
  6. Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery. Cancer J. 2003 Nov-Dec; 9(6):454-60.
    View in: PubMed
    Score: 0.048
  7. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res. 2003 Sep 15; 63(18):5874-8.
    View in: PubMed
    Score: 0.048
  8. Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible? J Urol. 2003 Mar; 169(3):964-8.
    View in: PubMed
    Score: 0.046
  9. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002 Oct 15; 62(20):5974-9.
    View in: PubMed
    Score: 0.045
  10. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
    View in: PubMed
    Score: 0.042
  11. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001 Feb 15; 19(4):1030-9.
    View in: PubMed
    Score: 0.040
  12. Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am J Surg Pathol. 2000 Jun; 24(6):859-63.
    View in: PubMed
    Score: 0.038
  13. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 2000 Feb 01; 60(3):756-9.
    View in: PubMed
    Score: 0.037
  14. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology. 2000 Jan; 55(1):41-5.
    View in: PubMed
    Score: 0.037
  15. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 1998 Aug; 29(8):856-62.
    View in: PubMed
    Score: 0.034
  16. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 07 13; 377(2):132-142.
    View in: PubMed
    Score: 0.031
  17. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer. 1995 Dec 15; 76(12):2530-4.
    View in: PubMed
    Score: 0.028
  18. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995 Jan; 153(1):104-10.
    View in: PubMed
    Score: 0.026
  19. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. J Urol. 1994 Jun; 151(6):1558-64.
    View in: PubMed
    Score: 0.025
  20. A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis. BJU Int. 2011 Feb; 107(3):389-95.
    View in: PubMed
    Score: 0.019
  21. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010 Jul; 184(1):149-56.
    View in: PubMed
    Score: 0.019
  22. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.017
  23. Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features. J Urol. 2008 May; 179(5):1762-7; discussion 1767.
    View in: PubMed
    Score: 0.016
  24. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest. 2007 Jul; 117(7):1876-83.
    View in: PubMed
    Score: 0.016
  25. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol. 2007 Oct; 38(10):1501-7.
    View in: PubMed
    Score: 0.016
  26. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.015
  27. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
    View in: PubMed
    Score: 0.014
  28. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl. 2005 May; (216):8-19.
    View in: PubMed
    Score: 0.013
  29. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol. 2004 Aug; 172(2):508-11.
    View in: PubMed
    Score: 0.013
  30. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology. 2004 Jun; 63(6):1191-7.
    View in: PubMed
    Score: 0.013
  31. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. 2003 Dec; 170(6 Pt 1):2292-5.
    View in: PubMed
    Score: 0.012
  32. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003 Nov; 170(5):1792-7.
    View in: PubMed
    Score: 0.012
  33. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4792-801.
    View in: PubMed
    Score: 0.012
  34. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003 Oct 01; 21(19):3573-9.
    View in: PubMed
    Score: 0.012
  35. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003 Aug 01; 63(15):4662-70.
    View in: PubMed
    Score: 0.012
  36. Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res. 2003 Jul-Aug; 23(4):3413-8.
    View in: PubMed
    Score: 0.012
  37. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification]. Nihon Hinyokika Gakkai Zasshi. 2002 Jul; 93(5):595-601.
    View in: PubMed
    Score: 0.011
  38. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001 Jun 01; 19(11):2856-64.
    View in: PubMed
    Score: 0.010
  39. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999 May; 17(5):1499-507.
    View in: PubMed
    Score: 0.009
  40. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998 May 20; 90(10):766-71.
    View in: PubMed
    Score: 0.008
  41. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998 Jan 01; 82(1):168-75.
    View in: PubMed
    Score: 0.008
  42. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997 Jul; 50(1):93-9.
    View in: PubMed
    Score: 0.008
  43. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol. 1997 Jun; 157(6):2212-8.
    View in: PubMed
    Score: 0.008
  44. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer. 1997 Feb 01; 79(3):528-37.
    View in: PubMed
    Score: 0.008
  45. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol. 1996 Sep; 156(3):1059-63.
    View in: PubMed
    Score: 0.007
  46. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 1996 Jul; 48(1):47-57.
    View in: PubMed
    Score: 0.007
  47. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer. 1995 Jan 15; 75(2):522-9.
    View in: PubMed
    Score: 0.007
  48. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994 Nov; 152(5 Pt 2):1714-20.
    View in: PubMed
    Score: 0.006
  49. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994 Nov; 152(5 Pt 2):1843-9.
    View in: PubMed
    Score: 0.006
  50. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer. 1994 Jul 01; 74(1):104-14.
    View in: PubMed
    Score: 0.006
  51. Detection of microscopic extracapsular extension prior to radical prostatectomy for clinically localized prostate cancer. Br J Urol. 1994 Jul; 74(1):72-9.
    View in: PubMed
    Score: 0.006
  52. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem Suppl. 1994; 19:283-9.
    View in: PubMed
    Score: 0.006
  53. Ultrasonic detection of non-palpable seminal vesicle invasion: a clinicopathological study. Br J Urol. 1993 Nov; 72(5 Pt 2):799-808.
    View in: PubMed
    Score: 0.006
  54. Detection of residual prostate cancer after radiotherapy by sonographically guided needle biopsy. Urology. 1992 Apr; 39(4):358-63.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.